DK1848431T3 - LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS - Google Patents
LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS Download PDFInfo
- Publication number
- DK1848431T3 DK1848431T3 DK06734887.0T DK06734887T DK1848431T3 DK 1848431 T3 DK1848431 T3 DK 1848431T3 DK 06734887 T DK06734887 T DK 06734887T DK 1848431 T3 DK1848431 T3 DK 1848431T3
- Authority
- DK
- Denmark
- Prior art keywords
- rapamycin
- vitreous
- eye
- variations
- injection
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title claims description 211
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 91
- 201000010099 disease Diseases 0.000 title claims description 89
- 238000011282 treatment Methods 0.000 title claims description 70
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 442
- 229960002930 sirolimus Drugs 0.000 claims description 441
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 436
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 122
- 239000003814 drug Substances 0.000 claims description 118
- 239000000203 mixture Substances 0.000 claims description 118
- 229940124597 therapeutic agent Drugs 0.000 claims description 109
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 73
- 208000002780 macular degeneration Diseases 0.000 claims description 42
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 30
- 206010046851 Uveitis Diseases 0.000 claims description 17
- 208000001344 Macular Edema Diseases 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 11
- 206010025415 Macular oedema Diseases 0.000 claims description 11
- 201000010230 macular retinal edema Diseases 0.000 claims description 11
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 10
- 206010029113 Neovascularisation Diseases 0.000 claims description 9
- 208000002691 Choroiditis Diseases 0.000 claims description 8
- 208000003971 Posterior uveitis Diseases 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 206010038848 Retinal detachment Diseases 0.000 claims description 7
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 230000004264 retinal detachment Effects 0.000 claims description 7
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 6
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 6
- 206010038910 Retinitis Diseases 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000004340 degenerative myopia Effects 0.000 claims description 4
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 claims description 3
- 208000019878 Eales disease Diseases 0.000 claims description 3
- 201000002563 Histoplasmosis Diseases 0.000 claims description 3
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims description 3
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims description 3
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 claims description 3
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 3
- 210000001367 artery Anatomy 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000004379 myopia Effects 0.000 claims description 3
- 208000001491 myopia Diseases 0.000 claims description 3
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 206010073286 Pathologic myopia Diseases 0.000 claims 1
- 206010040925 Skin striae Diseases 0.000 claims 1
- 208000001309 degenerative myopia Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 291
- 238000002347 injection Methods 0.000 description 218
- 239000007924 injection Substances 0.000 description 218
- 210000001525 retina Anatomy 0.000 description 182
- 210000003161 choroid Anatomy 0.000 description 171
- 239000000243 solution Substances 0.000 description 147
- 241000283973 Oryctolagus cuniculus Species 0.000 description 129
- 238000009472 formulation Methods 0.000 description 89
- 210000003786 sclera Anatomy 0.000 description 78
- 210000001519 tissue Anatomy 0.000 description 71
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 60
- 238000005259 measurement Methods 0.000 description 55
- 238000000034 method Methods 0.000 description 48
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 47
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 47
- 238000012384 transportation and delivery Methods 0.000 description 44
- 239000000523 sample Substances 0.000 description 43
- 210000001742 aqueous humor Anatomy 0.000 description 38
- 206010064930 age-related macular degeneration Diseases 0.000 description 36
- 210000000795 conjunctiva Anatomy 0.000 description 35
- 238000011587 new zealand white rabbit Methods 0.000 description 31
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- 239000000725 suspension Substances 0.000 description 28
- 239000002609 medium Substances 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 25
- 230000002265 prevention Effects 0.000 description 25
- 239000012736 aqueous medium Substances 0.000 description 17
- 230000003111 delayed effect Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000012512 characterization method Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000004438 eyesight Effects 0.000 description 12
- 206010025421 Macule Diseases 0.000 description 11
- 230000033115 angiogenesis Effects 0.000 description 11
- 238000002428 photodynamic therapy Methods 0.000 description 11
- 230000002207 retinal effect Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 208000017442 Retinal disease Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000004393 visual impairment Effects 0.000 description 8
- 210000004087 cornea Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000843 anti-fungal effect Effects 0.000 description 6
- 229940121375 antifungal agent Drugs 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000006257 total synthesis reaction Methods 0.000 description 6
- 210000002159 anterior chamber Anatomy 0.000 description 5
- 201000007917 background diabetic retinopathy Diseases 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000000649 photocoagulation Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- 238000006421 Davidson Oxazole synthesis reaction Methods 0.000 description 4
- 206010015548 Euthanasia Diseases 0.000 description 4
- 241001655322 Streptomycetales Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000000554 iris Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000003504 photosensitizing agent Substances 0.000 description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 208000005598 Angioid Streaks Diseases 0.000 description 3
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 3
- 208000033825 Chorioretinal atrophy Diseases 0.000 description 3
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001506137 Rapa Species 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 206010058990 Venous occlusion Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000001497 fibrovascular Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002647 laser therapy Methods 0.000 description 3
- 238000013532 laser treatment Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 210000004127 vitreous body Anatomy 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- SRIDGLJAFSFWOP-UHFFFAOYSA-N Demethoxyrapamycin Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)CC(O)C(C)=CC(C)C(=O)C1 SRIDGLJAFSFWOP-UHFFFAOYSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000008069 Geographic Atrophy Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920003082 Povidone K 90 Polymers 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 206010038862 Retinal exudates Diseases 0.000 description 2
- 208000032107 Rigor Mortis Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940064804 betadine Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- SRIDGLJAFSFWOP-XOPIUEIMSA-N demethoxyrapamycin Chemical compound C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)/C(C)=C/C=C/C=C/C(C)CC(C)C(=O)CC(O)/C(C)=C/C(C)C(=O)C1 SRIDGLJAFSFWOP-XOPIUEIMSA-N 0.000 description 2
- -1 di-ester derivatives of rapamycin Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005710 macrocyclization reaction Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001957 retinal vein Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- OUNADCPYEMRCEK-AHTHDSRYSA-N (1R,9S,12S,15R,16E,18R,19R,21R,23S,24Z,26E,28E,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2CC\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 OUNADCPYEMRCEK-AHTHDSRYSA-N 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010011017 Corneal graft rejection Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010065630 Iris neovascularisation Diseases 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical class [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010033712 Papilloedema Diseases 0.000 description 1
- 206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 150000005690 diesters Chemical group 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000009540 indirect ophthalmoscopy Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000010746 intraretinal hemorrhage Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000009517 secondary packaging Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 210000001760 tenon capsule Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65179005P | 2005-02-09 | 2005-02-09 | |
| US66404005P | 2005-03-21 | 2005-03-21 | |
| US66430605P | 2005-03-21 | 2005-03-21 | |
| PCT/US2006/004962 WO2006086750A1 (en) | 2005-02-09 | 2006-02-09 | Liquid formulations for treatment of diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1848431T3 true DK1848431T3 (en) | 2016-04-18 |
Family
ID=36793384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06734887.0T DK1848431T3 (en) | 2005-02-09 | 2006-02-09 | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
Country Status (17)
| Country | Link |
|---|---|
| US (11) | US20060258698A1 (enExample) |
| EP (3) | EP1848431B1 (enExample) |
| JP (2) | JP2008530127A (enExample) |
| KR (3) | KR20070104931A (enExample) |
| CN (1) | CN104147005B (enExample) |
| AU (2) | AU2006213588B2 (enExample) |
| BR (2) | BRPI0607606B1 (enExample) |
| CA (2) | CA2597590A1 (enExample) |
| CY (1) | CY1117357T1 (enExample) |
| DK (1) | DK1848431T3 (enExample) |
| ES (1) | ES2564194T3 (enExample) |
| GB (1) | GB2438544A (enExample) |
| HK (1) | HK1222537A1 (enExample) |
| HU (1) | HUE027352T2 (enExample) |
| PL (1) | PL1848431T3 (enExample) |
| SI (1) | SI1848431T1 (enExample) |
| WO (2) | WO2006086744A1 (enExample) |
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| CA2539324A1 (en) * | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| US8288362B2 (en) | 2004-05-07 | 2012-10-16 | S.K. Pharmaceuticals, Inc. | Stabilized glycosaminoglycan preparations and related methods |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| BRPI0607606B1 (pt) * | 2005-02-09 | 2021-06-22 | Santen Pharmaceutical, Co., Ltd. | Formulação líquida |
| AU2006227116A1 (en) * | 2005-03-21 | 2006-09-28 | Santen Pharmaceutical Co., Ltd. | Drug delivery systems for treatment of diseases or conditions |
| US20060222596A1 (en) | 2005-04-01 | 2006-10-05 | Trivascular, Inc. | Non-degradable, low swelling, water soluble radiopaque hydrogel polymer |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| AU2013200089B2 (en) * | 2006-02-09 | 2016-03-03 | Santen Pharmaceutical Co., Ltd | Stable formulations, and methods of their preparation and use |
| CN101605529B (zh) | 2006-02-09 | 2013-03-13 | 参天制药株式会社 | 稳定制剂及它们的制备和使用方法 |
| BRPI0709016A2 (pt) | 2006-03-23 | 2011-06-21 | Macusight Inc | formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular |
| US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| US7872068B2 (en) | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
| WO2008021088A2 (en) * | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
| RU2010104916A (ru) * | 2006-08-16 | 2011-08-20 | Михаил В. Благосклонный (US) | Способ профилактики и лечения возрастных заболеваний |
| US9205080B2 (en) | 2006-11-16 | 2015-12-08 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mTOR inhibitors |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| WO2008120249A1 (en) * | 2007-03-30 | 2008-10-09 | Sifi S.P.A. | Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| AU2014201863B2 (en) * | 2007-04-30 | 2017-02-02 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| CN101687042A (zh) * | 2007-07-20 | 2010-03-31 | 爱尔康公司 | 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂 |
| WO2009018333A2 (en) * | 2007-07-30 | 2009-02-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
| CN101827523A (zh) * | 2007-08-16 | 2010-09-08 | 马库赛特公司 | 用于治疗眼部疾病或病症的制剂 |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| US20090118262A1 (en) * | 2007-11-01 | 2009-05-07 | Rohrs Brian R | Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery |
| WO2009067217A1 (en) * | 2007-11-20 | 2009-05-28 | Ceramoptec Industries, Inc. | Pdt assisted scar prevention and vision correction |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| EP2365802B1 (en) | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules of rapamycin and use for treating cancer |
| DE102008059201A1 (de) * | 2008-11-27 | 2010-06-02 | GÖPFERICH, Achim, Prof. Dr. | In situ präzipitierende Arzneistofflösungen |
| WO2010065024A1 (en) * | 2008-12-05 | 2010-06-10 | Kador Peter F | Topical treatment of cataracts in dogs |
| US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
| WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| JP2010260857A (ja) * | 2009-04-10 | 2010-11-18 | Santen Pharmaceut Co Ltd | シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤 |
| CN102612564B (zh) * | 2009-04-10 | 2015-08-26 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
| EP2427174A4 (en) * | 2009-05-04 | 2014-01-15 | Santen Pharmaceutical Co Ltd | HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE |
| AU2010249683B2 (en) | 2009-05-18 | 2015-06-25 | Glaukos Corporation | Drug eluting ocular implant |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US20100305046A1 (en) | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Stable cyclosporine containing ophthalmic emulsion for treating dry eyes |
| AU2014250656B2 (en) * | 2009-06-02 | 2016-05-05 | Johnson & Johnson Surgical Vision, Inc. | Omega-3 oil containing ophthalmic emulsions |
| US20100303915A1 (en) * | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Therapeutic opthalmic emulsions |
| US9480645B2 (en) * | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
| MX338355B (es) | 2009-06-09 | 2016-04-13 | Aurinia Pharmaceuticals Inc | Sistemas de suministro de farmaco topico para uso oftalmico. |
| WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
| TWI492769B (zh) * | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| EP2308468A1 (en) * | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| ES2661812T3 (es) | 2009-10-16 | 2018-04-04 | Mochida Pharmaceutical Co., Ltd. | Composiciones |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| CN102753150A (zh) | 2010-01-12 | 2012-10-24 | 诺沃—诺迪斯克有限公司 | 用于口服给予胰岛素肽的药物组合物 |
| US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
| WO2012067224A1 (ja) * | 2010-11-19 | 2012-05-24 | 日本水産株式会社 | 角膜上皮障害及び／又は結膜上皮障害の治療又は予防剤 |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| KR101214362B1 (ko) * | 2011-02-15 | 2012-12-21 | 한림대학교 산학협력단 | Ｆｋ506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물 |
| CN102653779B (zh) * | 2011-03-04 | 2014-02-19 | 北京科润三联生物技术有限责任公司 | 一种新型重组抗菌多肽药物的制备方法 |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
| US8716363B2 (en) | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
| AU2012347926B2 (en) | 2011-12-05 | 2018-03-15 | Incept, Llc | Medical organogel processes and compositions |
| CN103127052A (zh) * | 2011-12-05 | 2013-06-05 | 维瑞斯特姆有限公司 | 治疗组合物和相关使用方法 |
| US8703786B2 (en) * | 2011-12-07 | 2014-04-22 | Texas Southern University | Etravirine formulations and uses thereof |
| EP2906214A1 (en) | 2012-10-12 | 2015-08-19 | The Board of Regents of The University of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| ES2969933T3 (es) | 2012-12-31 | 2024-05-23 | Jrx Biotechnology Inc | Formulaciones farmacéuticas tópicas líquidas en nanoemulsión |
| DK2968281T3 (da) | 2013-03-13 | 2020-11-02 | Univ Texas | Mtor-hæmmere til forebyggelse af vækst af tarmpolyp |
| WO2014169708A1 (en) * | 2013-04-18 | 2014-10-23 | The Hong Kong University Of Science And Technology | Biocompatible in situ hydrogel |
| EA201690621A1 (ru) * | 2013-09-20 | 2016-07-29 | Сантен Фармасьютикал Ко., Лтд. | Полиэтиленгликольсодержащие композиции |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| AU2014373683B2 (en) * | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| EP3131546B1 (en) | 2014-04-16 | 2022-02-16 | Rapamycin Holdings, Inc. | Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs) |
| EP2946788A1 (en) | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
| CA2950187A1 (en) | 2014-05-29 | 2015-12-03 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| CA2963871A1 (en) * | 2014-10-08 | 2016-04-14 | Maamar ACHACHA | Altrenogest formulation and uses thereof for estrus synchronisation in animals |
| US20180015166A1 (en) * | 2015-02-02 | 2018-01-18 | Santen Pharmaceutical Co., Ltd | Polyaphrons and palpebral administration thereof |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| HK1245135A1 (zh) * | 2015-03-05 | 2018-08-24 | Allergan, Inc. | 用於眼科药物递送的自乳化药物递送体系(sedds) |
| ES2969514T3 (es) * | 2015-03-18 | 2024-05-21 | Santen Pharmaceutical Co Ltd | Composición farmacéutica de liberación sostenida |
| MX2017014776A (es) | 2015-05-20 | 2018-02-15 | Novartis Ag | Combinacion farmaceutica de everolimus con dactolisib. |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| CN108024914A (zh) | 2015-09-17 | 2018-05-11 | Jrx生物技术有限公司 | 改善皮肤的水合作用或润湿作用的方法 |
| WO2017047618A1 (ja) * | 2015-09-18 | 2017-03-23 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| SG11201802091RA (en) | 2015-09-18 | 2018-04-27 | Santen Pharmaceutical Co Ltd | Fungal keratitis prophylactic or therapeutic agent |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| EP3442479A1 (en) | 2016-04-20 | 2019-02-20 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3463349B1 (en) * | 2016-05-25 | 2021-08-04 | Santen Pharmaceutical Co., Ltd. | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema |
| KR20190036520A (ko) | 2016-06-27 | 2019-04-04 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물 |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| BR112018077259A2 (pt) | 2016-06-30 | 2019-06-18 | Durect Corporation | formulações depot |
| BR112019010470A2 (pt) | 2016-11-23 | 2019-09-10 | Novartis Ag | métodos de realce de resposta imune com everolimo, dactolisib ou ambos |
| EA201990127A1 (ru) * | 2016-12-30 | 2020-08-18 | Дьюрект Корпорейшн | Депо-препарат |
| IL267869B2 (en) | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| AR111103A1 (es) * | 2017-02-17 | 2019-06-05 | Santen Pharmaceutical Co Ltd | Recipiente para sellado de formulaciones y uso del mismo |
| AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20210154372A1 (en) | 2017-05-15 | 2021-05-27 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
| KR20200069261A (ko) * | 2017-05-30 | 2020-06-16 | 엑시모어 엘티디. | 항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법 |
| CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN116120314A (zh) | 2017-06-30 | 2023-05-16 | 加利福尼亚大学董事会 | 用于调节毛发生长的组合物和方法 |
| US20200208103A1 (en) * | 2017-07-20 | 2020-07-02 | Riken | Method for maturation of retinal tissue containing continuous epithelium |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP4652999A2 (en) * | 2018-05-01 | 2025-11-26 | Chibi, Inc. | Liquid depot for non-invasive sustained delivery of agents to the eye |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| EP3841086B1 (en) | 2018-08-20 | 2025-04-23 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
| AU2019382044B2 (en) * | 2018-11-14 | 2025-07-17 | Smilebiotek Zhuhai Limited | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
| CN113226389B (zh) | 2018-11-14 | 2022-11-08 | 乐通公司 | 在经改性设备表面上具有药物洗脱涂层的医疗设备 |
| JP7443361B2 (ja) * | 2018-12-03 | 2024-03-05 | 珠海岐微生物科技有限公司 | 加齢黄斑変性症の治療方法 |
| US20220079899A1 (en) * | 2019-01-14 | 2022-03-17 | The Regents Of The University Of California | Compositions and methods for treating ocular conditions |
| CN113939324A (zh) | 2019-04-08 | 2022-01-14 | 巴德外周血管股份有限公司 | 在经改性装置表面上具有药物洗脱涂层的医疗装置 |
| EA202192738A1 (ru) | 2019-04-12 | 2022-03-17 | С4 Терапьютикс, Инк. | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos |
| JP7682512B2 (ja) | 2019-09-13 | 2025-05-26 | アルデイラ セラピューティクス， インコーポレイテッド | メトトレキサートの眼科用製剤 |
| CN115916183A (zh) * | 2020-01-10 | 2023-04-04 | 布里奥里生物技术公司 | 含有罗非昔布的局部用组合物及其制备和使用方法 |
| JP2023515073A (ja) | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| MX2022010952A (es) | 2020-03-05 | 2022-10-07 | C4 Therapeutics Inc | Compuestos para la degradacion dirigida de brd9. |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2022271702A1 (en) * | 2021-06-21 | 2022-12-29 | Palvella Therapeutics, Inc. | Methods and compositions for treating gorlin syndrome |
| EP4525862A1 (en) | 2022-05-20 | 2025-03-26 | Dermbiont, Inc. | Compositions and formulations for use of a pk inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (270)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2007538A (en) * | 1934-04-10 | 1935-07-09 | Louis Stern Company | Bracelet end hook |
| US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3828777A (en) | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
| US3914402A (en) | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
| US3926188A (en) | 1974-11-14 | 1975-12-16 | Alza Corp | Laminated drug dispenser |
| US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
| US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| FR2382240A1 (fr) | 1977-03-03 | 1978-09-29 | Mouls Pierre | Dispositif permettant d'instiller des liquides medicamenteux dans l'oeil |
| US4300557A (en) | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
| AU543727B2 (en) | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
| IT1141715B (it) | 1980-06-06 | 1986-10-08 | Sadepan Chimica Spa | Collante a base di resina urea-formaldeide additivato con ligninsolfonato di calcio e/o ammonio,resina urea formaldeide modificata con ligninsolfonato di calcio e/o ammonio e metodo di produzione degli stessi,per la preparazione di pannelli agglomerati di legno |
| US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
| US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
| EP0391909B1 (en) | 1987-09-03 | 1994-08-17 | The University Of Georgia Research Foundation, Inc. | Ocular cyclosporin composition |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| EP0356399A3 (en) * | 1988-08-26 | 1991-03-20 | Sandoz Ag | Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them |
| US4946450A (en) | 1989-04-18 | 1990-08-07 | Biosource Genetics Corporation | Glucan/collagen therapeutic eye shields |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5883082A (en) | 1990-08-14 | 1999-03-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for preventing and treating allograft rejection |
| US5192773A (en) | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
| DE4022553A1 (de) | 1990-07-16 | 1992-01-23 | Hund Helmut Gmbh | Vorrichtung zur hochreproduzierbaren applikation definierter volumina von loesungen und suspensionen diagnostisch oder therapeutisch wirksamer substanzen auf der cornea-oberflaeche |
| JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
| US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5290892A (en) * | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
| CA2054983A1 (en) | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| JP3158437B2 (ja) * | 1991-04-26 | 2001-04-23 | 藤沢薬品工業株式会社 | 眼疾患に対するマクロライド化合物の使用 |
| US5565560A (en) | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| US5120725A (en) * | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
| ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
| US5457111A (en) | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
| US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| PH30923A (en) * | 1992-03-30 | 1997-12-23 | American Home Prod | Rapamycin formulation for iv injection. |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| FR2690846B1 (fr) | 1992-05-05 | 1995-07-07 | Aiache Jean Marc | Forme galenique pour administration oculaire et procede de preparation. |
| US5858340A (en) * | 1992-05-22 | 1999-01-12 | The Procter & Gamble Company | Cosmetic compositions |
| WO1994005257A1 (en) | 1992-09-08 | 1994-03-17 | Allergan, Inc. | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| EP0669127B1 (en) * | 1992-11-18 | 1999-08-11 | Fujisawa Pharmaceutical Co., Ltd. | Prolonged-action pharmaceutical preparation |
| CA2156065A1 (en) | 1993-03-17 | 1994-09-29 | Rolf Wagner | Macrocyclic amide and urea immunomodulators |
| GB2278780B (en) | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
| US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| PT1155689E (pt) * | 1993-07-19 | 2007-01-31 | Angiotech Pharm Inc | Composições anti-angiogenicas e metodos de utilização |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5516770A (en) | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
| IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| IL111003A0 (en) | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| PL314238A1 (en) | 1993-12-17 | 1996-09-02 | Sandoz Ltd | Rapamycin derivatives |
| US5788687A (en) | 1994-02-01 | 1998-08-04 | Caphco, Inc | Compositions and devices for controlled release of active ingredients |
| US5773021A (en) | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
| US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| NZ283658A (en) | 1994-04-04 | 1999-09-29 | William R Freeman | Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides) |
| US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| US5621108A (en) * | 1994-12-05 | 1997-04-15 | Trustees Of The University Of Pennsylvania | Processes and intermediates for preparing macrocycles |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| CN1283324C (zh) | 1995-05-14 | 2006-11-08 | 奥普通诺尔有限公司 | 眼内植入物、植入装置、以及植入方法 |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| US5696135A (en) | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
| US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| JPH0930966A (ja) | 1995-07-24 | 1997-02-04 | Gakuzo Tamura | 眼科用新規製剤 |
| AU719613B2 (en) | 1995-09-19 | 2000-05-11 | Astellas Pharma Inc. | Aerosol compositions |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| AU712015B2 (en) | 1995-10-31 | 1999-10-28 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
| GB9601120D0 (en) * | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| CA2246356A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist |
| US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| US5743274A (en) | 1996-03-18 | 1998-04-28 | Peyman; Gholam A. | Macular bandage for use in the treatment of subretinal neovascular members |
| US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
| JP3309175B2 (ja) | 1996-03-25 | 2002-07-29 | 参天製薬株式会社 | タンパク性薬物含有強膜プラグ |
| JPH09315954A (ja) | 1996-05-30 | 1997-12-09 | Kita:Kk | 眼科手術後の眼組織混濁防止剤。 |
| GB9710962D0 (en) * | 1997-05-28 | 1997-07-23 | Univ Cambridge Tech | Polyketides and their synthesis |
| RU2123314C1 (ru) | 1996-06-27 | 1998-12-20 | Павлова Татьяна Вячеславовна | Способ постановки ирригационной системы в теноново пространство |
| EP1208847B8 (en) * | 1996-07-30 | 2007-02-14 | Novartis AG | Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions |
| US6142969A (en) | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
| US6007510A (en) | 1996-10-25 | 1999-12-28 | Anamed, Inc. | Implantable devices and methods for controlling the flow of fluids within the body |
| AUPO427196A0 (en) | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| JPH10218787A (ja) | 1997-02-06 | 1998-08-18 | Akio Okamoto | 神経栄養因子による眼科用組成物 |
| TW450810B (en) | 1997-02-20 | 2001-08-21 | Fujisawa Pharmaceutical Co | Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases |
| US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| EP1003569B1 (en) | 1997-08-11 | 2004-10-20 | Allergan, Inc. | Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture |
| US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
| US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| US20060198867A1 (en) | 1997-09-25 | 2006-09-07 | Abbott Laboratories, Inc. | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
| US20030190286A1 (en) | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
| HUP0004170A3 (en) | 1997-10-22 | 2001-12-28 | Ponikau Jens Rochester | Methods and materials for treating and preventing inflammation ofmucosal tissue |
| AR043071A1 (es) | 1997-10-31 | 2005-07-20 | Abbott Lab | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica |
| CZ287497B6 (cs) | 1997-12-30 | 2000-12-13 | Galena, A. S. | Topické oční přípravky s imunosupresivními látkami |
| WO1999037667A1 (en) | 1998-01-23 | 1999-07-29 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| DE19810655A1 (de) | 1998-03-12 | 1999-09-16 | Univ Eberhard Karls | Arzneimittel mit einem Gehalt an Ciclosporin |
| DE69936381T2 (de) | 1998-03-13 | 2007-10-31 | The Johns Hopkins University School Of Medicine | Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie |
| US6482802B1 (en) | 1998-05-11 | 2002-11-19 | Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
| US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| US6585958B1 (en) | 1998-07-24 | 2003-07-01 | Jago Research Ag | Medicinal aerosol formulations |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US6384056B1 (en) | 1998-08-14 | 2002-05-07 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters or ketones for vision and memory disorders |
| US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
| US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
| US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
| US6632836B1 (en) | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
| US6472370B1 (en) | 1998-11-17 | 2002-10-29 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating post traumatic stress disorder |
| GB9826882D0 (en) | 1998-12-07 | 1999-01-27 | Novartis Ag | Organic compounds |
| CN1236813C (zh) * | 1998-12-11 | 2006-01-18 | 药品处理公司 | 水难溶性药物的自乳化组合物 |
| US6399655B1 (en) | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
| CZ20012340A3 (cs) * | 1998-12-23 | 2001-11-14 | G. D. Searle Llc | Kombinace inhibitorů transportu kyčelní ľlučové kyseliny a proteinových inhibitorů cholesteryl-esterového přenosu pro kardiovaskulární indikace |
| KR20010099928A (ko) | 1998-12-24 | 2001-11-09 | 우에노 류지 | 시세포 기능 질환 치료제 |
| US6864232B1 (en) | 1998-12-24 | 2005-03-08 | Sucampo Ag | Agent for treating visual cell function disorder |
| WO2000040089A1 (en) | 1999-01-05 | 2000-07-13 | Massachusetts Eye And Ear Infirmary | Targeted transscleral controlled release drug delivery to the retina and choroid |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| WO2000066122A1 (en) | 1999-04-30 | 2000-11-09 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| MXPA01011981A (es) * | 1999-05-24 | 2003-09-04 | Sonus Pharma Inc | Vehiculo de emulsion para farmacos poco solubles. |
| US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| JP2001064198A (ja) | 1999-08-24 | 2001-03-13 | Teika Seiyaku Kk | 角膜疾患治療剤 |
| BR0015053A (pt) | 1999-10-18 | 2002-07-02 | Fujisawa Pharmaceutical Co | Método para produzir uma preparação de lipossoma e preparação de lipossoma |
| US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| AU775149B2 (en) | 1999-10-21 | 2004-07-22 | Alcon Inc. | Sub-tenon drug delivery |
| KR100732262B1 (ko) | 1999-10-21 | 2007-06-25 | 알콘, 인코퍼레이티드 | 약물 전달 장치 |
| HK1049785A1 (zh) | 1999-10-22 | 2003-05-30 | Biogen, Inc. | Cd40:cd154结合阻断剂在治疗眼睛免疫并发症的用途 |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| WO2001030337A2 (en) * | 1999-10-22 | 2001-05-03 | Orbon Corporation | Ophthalmic formulation of dopamine antagonists |
| WO2001034816A1 (en) | 1999-10-29 | 2001-05-17 | Kosan Biosciences, Inc. | Rapamycin analogs |
| RU2149615C1 (ru) | 1999-11-10 | 2000-05-27 | Нестеров Аркадий Павлович | Способ введения лекарственных препаратов при заболеваниях заднего отрезка глаза |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| SK8562002A3 (en) | 1999-12-23 | 2003-10-07 | Pfizer Prod Inc | Pharmaceutical compositions providing enhanced drug concentrations |
| US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| GB0003932D0 (en) | 2000-02-18 | 2000-04-12 | Novartis Ag | Pharmaceutical compositions |
| US6489335B2 (en) | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| ATE250924T1 (de) | 2000-04-07 | 2003-10-15 | Medidom Lab | Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel |
| US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
| CN1127955C (zh) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | 一种眼前段及眼表免疫相关性疾病治疗药物 |
| WO2002017831A2 (en) * | 2000-08-30 | 2002-03-07 | John Hopkins University | Devices for intraocular drug delivery |
| CN1204919C (zh) | 2000-08-30 | 2005-06-08 | 中国科学院化学研究所 | 长效环孢素眼内释药体系 |
| AU2001296558A1 (en) | 2000-10-03 | 2002-04-15 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| US20050084514A1 (en) * | 2000-11-06 | 2005-04-21 | Afmedica, Inc. | Combination drug therapy for reducing scar tissue formation |
| US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| US6534693B2 (en) | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
| ATE306951T1 (de) | 2000-11-29 | 2005-11-15 | Allergan Inc | Verhinderung von transplantatabstossung im auge |
| ES2294043T3 (es) | 2001-01-03 | 2008-04-01 | BAUSCH & LOMB INCORPORATED | Dispositivos de liberacion prolongada de medicamentos que comprenden nucleos recubiertos de medicamentos. |
| DK2314293T3 (en) | 2001-01-16 | 2017-04-18 | Vascular Therapies Llc | IMPLANTABLE DEVICE CONTAINING RESORBABLE MATERIAL MATERIAL AND RAPAMYCINE FOR PREVENTION OR TREATMENT OF VASCULOPROLIFERATIVE DISEASES |
| US7181287B2 (en) * | 2001-02-13 | 2007-02-20 | Second Sight Medical Products, Inc. | Implantable drug delivery device |
| LT2762140T (lt) | 2001-02-19 | 2017-06-26 | Novartis Ag | Solidinių smegenų navikų gydymas rapamicino dariniu |
| US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| AR033151A1 (es) | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
| US7563255B2 (en) * | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
| JP2002332225A (ja) | 2001-05-09 | 2002-11-22 | Lion Corp | 眼科用組成物 |
| EP2316394B1 (en) | 2001-06-12 | 2016-11-23 | The Johns Hopkins University | Reservoir device for intraocular drug delivery |
| US6787179B2 (en) | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
| US7034037B2 (en) * | 2001-06-29 | 2006-04-25 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin |
| KR20040019034A (ko) * | 2001-07-06 | 2004-03-04 | 수캄포 아게 | 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물 |
| WO2003007944A1 (en) | 2001-07-20 | 2003-01-30 | Qlt, Inc. | Treatment of macular edema with photodynamic therapy |
| AR035293A1 (es) | 2001-08-23 | 2004-05-05 | Novartis Ag | Composicion oftalmica. |
| US6812220B2 (en) | 2001-08-29 | 2004-11-02 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US6656460B2 (en) | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
| US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| EA006746B1 (ru) * | 2001-11-09 | 2006-04-28 | Айтек Фармасьютикалз | Способы лечения глазных неоваскулярных заболеваний |
| US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
| WO2003051385A1 (de) | 2001-12-14 | 2003-06-26 | Jagotec Ag | Arzneiformulierung enthaltend ciclosporin und deren verwendung |
| GB0200429D0 (en) | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
| DE60313299T2 (de) | 2002-03-01 | 2008-01-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Selbstemulgierende systeme zur abgabe von taxoiden |
| WO2003074029A1 (en) | 2002-03-07 | 2003-09-12 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
| AU2003227827B2 (en) | 2002-03-12 | 2008-09-25 | Ethypharm | Composition having gelling properties for the prolonged delivery of bioactive substances |
| EP1531804A1 (en) | 2002-05-03 | 2005-05-25 | The Queen Elizabeth Hospital Research Foundation Inc., | Method of inhibiting angiogenesis |
| CN1456350A (zh) | 2002-05-10 | 2003-11-19 | 刘继东 | 环孢素眼用凝胶 |
| NZ518997A (en) | 2002-05-16 | 2004-12-24 | Interag | Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent |
| US20040057958A1 (en) * | 2002-05-17 | 2004-03-25 | Waggoner David W. | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same |
| US7026374B2 (en) * | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
| EP2277898A3 (en) | 2002-07-16 | 2011-06-01 | Biotica Technology Limited | Rapamycin analogues |
| KR101131794B1 (ko) | 2002-07-30 | 2012-03-30 | 와이어쓰 엘엘씨 | Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법 |
| US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| CN1674896A (zh) | 2002-08-09 | 2005-09-28 | 苏坎波制药有限公司 | 含有fk506衍生物的药物组合物及其用于治疗过敏性疾病的用途 |
| US20050031650A1 (en) | 2002-08-26 | 2005-02-10 | Ethypharm | Composition with gelling properties for the sustained delivery of bioactive substances |
| AU2003272471B2 (en) | 2002-09-18 | 2010-10-07 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
| US20050143363A1 (en) | 2002-09-29 | 2005-06-30 | Innorx, Inc. | Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| CA2508303C (en) | 2002-12-04 | 2012-10-23 | Santen Pharmaceutical Co., Ltd. | Drug delivery system using subconjunctival depot |
| AU2003293529A1 (en) | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| AR042890A1 (es) | 2003-01-16 | 2005-07-06 | Sucampo Pharmaceuticals Inc | Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido |
| WO2004074445A2 (en) | 2003-02-17 | 2004-09-02 | Cold Spring Harbor Laboratory | Model for studying the role of genes in tumor resistance to chemotherapy |
| US20050074497A1 (en) | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| WO2004096261A1 (es) | 2003-05-02 | 2004-11-11 | Arturo Jimenez Bayardo | Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante |
| US7160867B2 (en) | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
| DK1635875T3 (da) * | 2003-06-26 | 2009-01-12 | Psivida Inc | In-situ-geldannende lægemiddeladministrationssystem |
| US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| EP1510206A1 (en) | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| CA2539324A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| US20050181018A1 (en) | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
| EP1681983A4 (en) | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
| US20060141049A1 (en) | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| JP2007517543A (ja) | 2003-11-20 | 2007-07-05 | アンジオテック インターナショナル アーゲー | ポリマー化合物とその使用法 |
| WO2005051444A2 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Soft tissue implants and anti-scarring agents |
| US7186518B2 (en) | 2003-11-21 | 2007-03-06 | Dade Behring Inc. | Method and composition useful for determining FK 506 |
| CA2548822C (en) | 2003-12-08 | 2015-08-11 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
| WO2005082376A1 (en) | 2004-02-26 | 2005-09-09 | Advanced Ocular Systems Limited | Tetracycline derivatives for the treatment of ocular pathologies |
| WO2005094279A2 (en) | 2004-03-25 | 2005-10-13 | The Rothberg Institute For Childhood Diseases | Immortalized human tuberous sclerosis null angiomyolipoma cell and method of use thereof |
| US7846940B2 (en) | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
| US20050245497A1 (en) | 2004-04-08 | 2005-11-03 | Penfold Philip L | Treatment of ophthalmic conditions |
| US20050232965A1 (en) | 2004-04-15 | 2005-10-20 | Robert Falotico | Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20050250804A1 (en) | 2004-05-06 | 2005-11-10 | Glenmark Pharmaceuticals Limited | Pharmaceutical gel formulations |
| US20080124400A1 (en) | 2004-06-24 | 2008-05-29 | Angiotech International Ag | Microparticles With High Loadings Of A Bioactive Agent |
| WO2006002399A2 (en) | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable implantable medical devices, methods and systems |
| US20060024350A1 (en) * | 2004-06-24 | 2006-02-02 | Varner Signe E | Biodegradable ocular devices, methods and systems |
| WO2006080951A2 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| US20060110428A1 (en) | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
| WO2006020755A2 (en) | 2004-08-10 | 2006-02-23 | Beth Israel Deaconess Medical Center, Inc. | Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics |
| WO2006023130A2 (en) | 2004-08-12 | 2006-03-02 | Surmodics, Inc. | Biodegradable controlled release bioactive agent delivery device |
| AR050374A1 (es) | 2004-08-20 | 2006-10-18 | Wyeth Corp | Forma polimorfica de rafampicina |
| EP1781672B1 (en) | 2004-08-27 | 2010-10-06 | Cordis Corporation | Solvent free amorphous rapamycin |
| EP3173072A1 (en) * | 2004-10-01 | 2017-05-31 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| MX2007003789A (es) | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
| EP1843805A4 (en) | 2004-11-09 | 2015-05-06 | Angiotech Pharm Inc | ANTIMICROBIAL NEEDLE COATING FOR ADVANCED INFUSION |
| CN101137369A (zh) * | 2005-02-09 | 2008-03-05 | 马库赛特公司 | 用于眼治疗的制剂 |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| BRPI0607606B1 (pt) | 2005-02-09 | 2021-06-22 | Santen Pharmaceutical, Co., Ltd. | Formulação líquida |
| GB0504995D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
| AU2006227116A1 (en) | 2005-03-21 | 2006-09-28 | Santen Pharmaceutical Co., Ltd. | Drug delivery systems for treatment of diseases or conditions |
| US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| JP2008535847A (ja) | 2005-04-08 | 2008-09-04 | サーモディクス，インコーポレイティド | 網膜下に送達するための持続放出インプラント |
| BRPI0612925A2 (pt) | 2005-04-27 | 2010-12-07 | Univ Florida Res Foudation Inc | uso de um composto, composição farmacêutica e kit |
| US8475776B2 (en) | 2005-04-28 | 2013-07-02 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| US20060247265A1 (en) | 2005-04-28 | 2006-11-02 | Clackson Timothy P | Therapies for treating disorders of the eye |
| ES2400916T3 (es) | 2005-06-08 | 2013-04-15 | Janssen Biotech, Inc. | Una terapia celular para degeneración ocular |
| US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
| EP1904056B1 (en) | 2005-07-18 | 2009-04-29 | Minu, L.L.C. | Use of a macrolide to restore corneal sensation |
| US20070134244A1 (en) | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
| DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| US20070173538A1 (en) | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| ATE446087T1 (de) | 2006-01-23 | 2009-11-15 | Yissum Res Dev Co | Mikrokügelchen mit nanokapseln, die ein lipophiles arzneimittel enthalten |
| CN101605529B (zh) | 2006-02-09 | 2013-03-13 | 参天制药株式会社 | 稳定制剂及它们的制备和使用方法 |
| BRPI0709016A2 (pt) | 2006-03-23 | 2011-06-21 | Macusight Inc | formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular |
-
2006
- 2006-02-09 BR BRPI0607606-8A patent/BRPI0607606B1/pt not_active IP Right Cessation
- 2006-02-09 US US11/351,761 patent/US20060258698A1/en not_active Abandoned
- 2006-02-09 EP EP06734887.0A patent/EP1848431B1/en active Active
- 2006-02-09 KR KR1020077020500A patent/KR20070104931A/ko not_active Ceased
- 2006-02-09 HU HUE06734887A patent/HUE027352T2/en unknown
- 2006-02-09 SI SI200632038A patent/SI1848431T1/sl unknown
- 2006-02-09 PL PL06734887T patent/PL1848431T3/pl unknown
- 2006-02-09 KR KR1020147002953A patent/KR101492584B1/ko not_active Expired - Fee Related
- 2006-02-09 US US11/351,844 patent/US20060182771A1/en not_active Abandoned
- 2006-02-09 WO PCT/US2006/004955 patent/WO2006086744A1/en not_active Ceased
- 2006-02-09 EP EP15198710.4A patent/EP3025713A1/en not_active Withdrawn
- 2006-02-09 JP JP2007555303A patent/JP2008530127A/ja active Pending
- 2006-02-09 CA CA002597590A patent/CA2597590A1/en not_active Abandoned
- 2006-02-09 CN CN201410320617.1A patent/CN104147005B/zh active Active
- 2006-02-09 KR KR1020077020502A patent/KR101387456B1/ko active Active
- 2006-02-09 US US11/352,092 patent/US8637070B2/en not_active Expired - Fee Related
- 2006-02-09 AU AU2006213588A patent/AU2006213588B2/en not_active Ceased
- 2006-02-09 CA CA2597596A patent/CA2597596C/en active Active
- 2006-02-09 EP EP06720678A patent/EP1853259A1/en not_active Withdrawn
- 2006-02-09 GB GB0715745A patent/GB2438544A/en active Pending
- 2006-02-09 WO PCT/US2006/004962 patent/WO2006086750A1/en not_active Ceased
- 2006-02-09 AU AU2006213673A patent/AU2006213673A1/en not_active Abandoned
- 2006-02-09 ES ES06734887.0T patent/ES2564194T3/es active Active
- 2006-02-09 DK DK06734887.0T patent/DK1848431T3/en active
- 2006-02-09 JP JP2007555305A patent/JP4974903B2/ja active Active
- 2006-02-09 BR BRPI0608152-5A patent/BRPI0608152A2/pt not_active IP Right Cessation
-
2010
- 2010-05-12 US US12/778,872 patent/US8367097B2/en active Active
-
2013
- 2013-01-14 US US13/741,103 patent/US8927005B2/en active Active
-
2014
- 2014-01-09 US US14/151,647 patent/US9387165B2/en not_active Expired - Fee Related
- 2014-11-25 US US14/553,947 patent/US9381153B2/en active Active
-
2016
- 2016-04-06 CY CY20161100276T patent/CY1117357T1/el unknown
- 2016-06-15 US US15/183,649 patent/US20170020809A1/en not_active Abandoned
- 2016-06-29 US US15/197,568 patent/US20160303093A1/en not_active Abandoned
- 2016-09-05 HK HK16110534.4A patent/HK1222537A1/en unknown
-
2017
- 2017-06-01 US US15/611,701 patent/US20170266109A1/en not_active Abandoned
- 2017-11-07 US US15/806,226 patent/US20180311152A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1848431T3 (en) | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS | |
| KR101478164B1 (ko) | 안정한 제제와 그 제조 및 사용 방법 | |
| JP7353292B2 (ja) | ネビボロールを含む医薬組成物 | |
| KR20100055482A (ko) | 안질환 또는 안이상의 치료를 위한 제제 | |
| JP7496778B2 (ja) | チモロールを含む医薬組成物 | |
| US20120114637A1 (en) | Mtor pathway inhibitors for treating ocular disorders | |
| KR20160135372A (ko) | 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 | |
| KR20150100670A (ko) | 레고라페닙을 함유하는 국소 안과 제약 조성물 | |
| Okka et al. | Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys | |
| RU2434633C2 (ru) | Фармацевтические препаративные формы латрункулина | |
| HK1110215B (en) | Liquid formulations for treatment of diseases or conditions | |
| JP2021523222A (ja) | 網膜への薬剤の持続送達のための点眼剤および方法 | |
| Kim | Targeted Drug Delivery Within the Eye | |
| HK1117391A (en) | Formulations for ocular treatment |